Friday, October 28, 2016

Lactulose Solution (Novartis Consumer Health)





1. Name Of The Medicinal Product



Lactulose Liquid Ph Eur



Lactulose Liquid EP


2. Qualitative And Quantitative Composition



Lactulose 67.0% w/v



3. Pharmaceutical Form



Oral Solution



4. Clinical Particulars



4.1 Therapeutic Indications



A. Chronic constipation.



B. Chronic portal systemic encephalopathy.



4.2 Posology And Method Of Administration



Adults








Initially:




15-30ml daily for first 2-3 days (45ml may be given in obstinate cases).




Maintenance:




10-15ml daily or according to the need of the patient



Children








Initially:




10-25ml daily for first 2-3 days.




Maintenance:




5-15ml daily or according to the need of the patient.



Dosage does not appear to be related to the age or weight of the child and should be adjusted to produce the required response.



Chronic portal systemic encephalopathy



Initially 30-50ml three times daily according to the requirements of the patient for adequate acidification of the colonic contents.



Use in the elderly



No evidence exists that elderly patients require different dosages or show different side-effects from younger patients.



4.3 Contraindications



In common with other preparations used for the treatment of constipation, Lactulose solution should not be used in patients with gastrointestinal obstruction. Lactulose solution should not be given to patients with galactosaemia or lactose intolerance.



4.4 Special Warnings And Precautions For Use



Prolonged use of Lactulose in children may contribute to the development of dental caries. Patients should be instructed to pay careful attention to dental hygiene.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



There are no known interactions involving Lactulose.



4.6 Pregnancy And Lactation



Lactulose solution should be used with caution during the first trimester of pregnancy.



4.7 Effects On Ability To Drive And Use Machines



There is no evidence that Lactulose affects driving ability.



4.8 Undesirable Effects



Side-effects rarely occur after the administration of Lactulose solution. Mild transient effects such as abdominal distension or cramps and flatulence, which subside after the initial stages of treatment, have occasionally been reported. High doses may provoke nausea in some patients.



This can be minimised by administration with water, fruit juice or with meals.



4.9 Overdose



No cases of intoxication due to deliberate or accidental overdosage with Lactulose solution have been reported to the company.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



The active principle of Lactulose solution, lactulose, is neither broken down nor absorbed in the stomach and small intestine. In the colon it acts as a substrate for and promotes the growth of naturally occurring glycolytic micro-organisms, and is broken down to lactic acid. The pH of the intestinal contents is lowered, the growth of acidophilic flora is promoted and the putrefactive micro-organisms are suppressed. This reduces the formation of ammonia and amines and their absorption from the gut, thus leading to a fall in blood ammonia levels (responsible for hepatic encephalopathy). By normalising the intestinal flora Lactulose solution ensures the passage of normal stools, without excessive peristalsis.



5.2 Pharmacokinetic Properties



Not appropriate.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber which are additional to those already included in other sections of the Summary of Product Characteristics.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Other sugars (lactose, galactose, tagatose and other ketoses)



Purified water



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



Do not store above 25°C.



6.5 Nature And Contents Of Container



Amber glass bottles, plastic bottles (HDPE), PET bottles with polyethylene closure (polyethylene wad faced with PP. PVDC or PET lining), containing 200 ml, 300 ml, 500 ml or 1 litre of Lactulose solution.



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



Administrative Data


7. Marketing Authorisation Holder



Novartis Consumer Health UK Limited



Trading as Novartis Consumer Health



Wimblehurst Road



Horsham



West Sussex



RH12 5AB



UK



8. Marketing Authorisation Number(S)



PL 00030/0175



9. Date Of First Authorisation/Renewal Of The Authorisation



10 April 2000



10. Date Of Revision Of The Text



4th January 2006



Legal category


P





Thursday, October 27, 2016

Twinrix Adult, suspension for injection





1. Name Of The Medicinal Product



Twinrix Adult, suspension for injection



Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).


2. Qualitative And Quantitative Composition






















1 dose (1 ml) contains:




 




 




 




Hepatitis A virus (inactivated)1,2




720 ELISA Units




Hepatitis B surface antigen3,4




20 micrograms




 




 




1Produced on human diploid (MRC-5) cells




 




2Adsorbed on aluminium hydroxide, hydrated




0.05 milligrams Al3+




3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology


 


4Adsorbed on aluminium phosphate




0.4 milligrams Al3+



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Suspension for injection.



Turbid white suspension.



4. Clinical Particulars



4.1 Therapeutic Indications



Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.



4.2 Posology And Method Of Administration



Posology



- Dosage



A dose of 1.0 ml is recommended for adults and adolescents 16 years of age and above.



- Primary vaccination schedule



The standard primary course of vaccination with Twinrix Adult consists of three doses, the first administered at the elected date, the second one month later and the third six months after the first dose.



In exceptional circumstances in adults, when travel is anticipated within one month or more after initiating the vaccination course, but where insufficient time is available to allow the standard 0, 1, 6 month schedule to be completed, a schedule of three intramuscular injections given at 0, 7 and 21 days may be used. When this schedule is applied, a fourth dose is recommended 12 months after the first dose.



The recommended schedule should be adhered to. Once initiated, the primary course of vaccination should be completed with the same vaccine.



- Booster dose



Long-term antibody persistence data following vaccination with Twinrix Adult are available up to 15 years after vaccination. The anti-HBs and anti-HAV antibody titres observed following a primary vaccination course with the combined vaccine are in the range of what is seen following vaccination with the monovalent vaccines. The kinetics of antibody decline are also similar. General guidelines for booster vaccination can therefore be drawn from experience with the monovalent vaccines.



Hepatitis B



The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.



For some categories of subjects or patients exposed to HBV (e.g; haemodialysis or immunocompromised patients) a precautionary attitude should be considered to ensure a protective antibody level



Hepatitis A



It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses as protection in the absence of detectable antibodies may be ensured by immunological memory. Guidelines for boosting are based on the assumption that antibodies are required for protection; anti-HAV antibodies have been predicted to persist for at least 10 years.



In situations where a booster dose of both hepatitis A and hepatitis B are desired, Twinrix Adult can be given. Alternatively, subjects primed with Twinrix Adult may be administered a booster dose of either of the monovalent vaccines.



Method of administration



Twinrix Adult is for intramuscular injection, preferably in the deltoid region.



Exceptionally the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders. However, this route of administration may result in suboptimal immune response to the vaccine. (see section 4.4).



4.3 Contraindications



Hypersensitivity to the active substances or to any of the excipients or neomycin.



Hypersensitivity after previous administration of hepatitis A and/or hepatitis B vaccines.



The administration of Twinrix Adult should be postponed in subjects suffering from acute severe febrile illness.



4.4 Special Warnings And Precautions For Use



It is possible that subjects may be in the incubation period of a hepatitis A or hepatitis B infection at the time of vaccination. It is not known whether Twinrix Adult will prevent hepatitis A and hepatitis B in such cases.



The vaccine will not prevent infection caused by other agents such as hepatitis C and hepatitis E and other pathogens known to infect the liver.



Twinrix Adult is not recommended for postexposure prophylaxis (e.g. needle stick injury).



The vaccine has not been tested in patients with impaired immunity. In haemodialysis patients and persons with an impaired immune system, adequate anti-HAV and anti-HBs antibody titers may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine.



Obesity (defined as BMI 2) has been observed to reduce the immune response to hepatitis A vaccines. A number of factors have been observed to reduce the immune response to hepatitis B vaccines. These factors include older age, male gender, obesity, smoking, route of administration, and some chronic underlying diseases. Consideration should be given to serological testing of those subjects who may be at risk of not achieving seroprotection following a complete course of Twinrix Adult. Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.



As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.



Since intradermal injection or intramuscular administration into the gluteal muscle could lead to a suboptimal response to the vaccine, these routes should be avoided. However, exceptionally Twinrix Adult can be administered subcutaneously to subjects with thrombocytopenia or bleeding disorders since bleeding may occur following an intramuscular administration to these subjects (see section 4.2.).



TWINRIX ADULT SHOULD UNDER NO CIRCUMSTANCES BE ADMINISTERED INTRAVASCULARLY.



As with any vaccine, a protective immune response may not be elicited in all vaccinees.



As with any injection procedure, vasovagal syncope can infrequently occur following administration of Twinrix Adult to adults and adolescents.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No data on concomitant administration of Twinrix Adult with specific hepatitis A immunoglobulin or hepatitis B immunoglobulin have been generated. However, when the monovalent hepatitis A and hepatitis B vaccines were administered concomitantly with specific immunoglobulins, no influence on seroconversion was observed although it may result in lower antibody titres.



Although the concomitant administration of Twinrix Adult and other vaccines has not specifically been studied, it is anticipated that, if different syringes and other injection sites are used, no interaction will be observed.



It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate response may not be achieved.



4.6 Pregnancy And Lactation



Pregnancy



The effect of Twinrix Adult on embryo-fetal, peri-natal and post-natal survival and development has been assessed in rats. This study did not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryonal/fetal development, parturition or post-natal development.



The effect of Twinrix Adult on embryo-fetal, peri-natal and post-natal survival and development has not been prospectively evaluated in clinical trials.



Data on outcomes of a limited number of pregnancies in vaccinated women do not indicate any adverse effects of Twinrix Adult on pregnancy or on the health of the fetus/newborn child. While it is not expected that recombinant hepatitis B virus surface antigen would have adverse effects on pregnancies or the fetus it is recommended that vaccination should be delayed until after delivery unless there is an urgent need to protect the mother against hepatitis B infection.



Breastfeeding



It is unknown whether Twinrix Adult is excreted in human breast milk. The excretion of Twinrix Adult in milk has not been studied in animals. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast-feeding to the child and the benefit of Twinrix Adult therapy to the woman.



4.7 Effects On Ability To Drive And Use Machines



Twinrix Adult has no or negligible influence on the ability to drive and use machines.



4.8 Undesirable Effects



• Clinical trials



The safety profile presented below is based on a pooled analysis of events per dose from more than 6,000 subjects who received either the standard 0, 1, 6 month schedule (n=5,683) or the accelerated 0, 7, 21 days schedule (n=320). In the two clinical trials in which Twinrix Adult was administered at 0, 7, 21 days, overall solicited general and local symptoms were reported with the same categories of frequency as defined below. After a fourth dose given at month 12, the incidence of systemic and local adverse reactions was comparable to that seen after vaccination at 0, 7, 21 days.



In comparative studies, it was noted that the frequency of solicited adverse events following the administration of Twinrix Adult is not different from the frequency of solicited adverse events following the administration of the monovalent vaccines.



Frequencies are reported as:














Very common:







Common:







Uncommon:







Rare:







Very rare:




< 1/10,000



* refers to adverse reactions observed in clinical trials performed with the paediatric formulation



Blood and lymphatic system disorders



Rare: lymphadenopathy



Nervous system disorders



Very common: headache



Uncommon: dizziness



Rare: hypoaesthesia, paraesthesia



Gastrointestinal disorders



Common: gastrointestinal symptoms, diarrhoea, nausea



Uncommon: vomiting, abdominal pain*



Skin and subcutaneous tissue disorders



Rare: rash, pruritus



Very rare: urticaria



Musculoskeletal and connective tissue disorders



Uncommon: myalgia



Rare: arthralgia



Metabolism and nutrition disorders



Rare: decreased appetite



Infections and infestations



Uncommon: upper respiratory tract infection



Vascular disorders



Rare: hypotension



General disorders and administration site conditions



Very common: pain and redness at the injection site, fatigue



Common: swelling at the injection site, injection site reactions (such as haematoma, pruritus and bruising), malaise



Uncommon: fever (



Rare: influenza like illness, chills



• Post-marketing surveillance



The following adverse reactions have been reported with either Twinrix or with GlaxoSmithKline monovalent hepatitis A or B vaccines:



Blood and lymphatic system disorders



Thrombocytopenia, thrombocytopenic purpura



Nervous system disorders



Encephalitis, encephalopathy, neuritis, neuropathy, paralysis, convulsions



Skin and subcutaneous tissue disorders



Angioneurotic oedema, lichen planus, erythema multiforme



Musculoskeletal and connective tissue disorders



Arthritis, muscular weakness



Infections and infestations



Meningitis



Vascular disorders



Vasculitis



Immune system disorders



Anaphylaxis, allergic reactions including anaphylactoid reactions and mimicking serum sickness



Following widespread use of the monovalent hepatitis A and/or hepatitis B vaccines, the following undesirable events have additionally been reported in temporal association with vaccination.



Investigations



Abnormal liver function tests



Nervous system disorders



Multiple sclerosis, myelitis, facial palsy, polyneuritis such as Guillain-Barré syndrome (with ascending paralysis), optic neuritis



4.9 Overdose



Cases of overdose have been reported during post-marketing surveillance. Adverse events reported following overdosage were similar to those reported with normal vaccine administration.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmaco-therapeutic group: Hepatitis vaccines, ATC code J07BC20.



Twinrix Adult is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated hepatitis A (HA) virus and purified hepatitis B surface antigen (HBsAg), separately adsorbed onto aluminium hydroxide and aluminium phosphate. The HA virus is propagated in MRC5 human diploid cells. HBsAg is produced by culture, in a selective medium, of genetically engineered yeast cells.



Twinrix Adult confers immunity against HAV and HBV infection by inducing specific anti-HAV and anti-HBs antibodies.



Protection against hepatitis A and hepatitis B develops within 2-4 weeks. In the clinical studies, specific humoral antibodies against hepatitis A were observed in approximately 94% of the adults one month after the first dose and in 100% one month after the third dose (i.e. month 7). Specific humoral antibodies against hepatitis B were observed in 70% of the adults after the first dose and approximately 99% after the third dose.



The 0, 7 and 21 day primary schedule plus a fourth dose at month 12 is for use in exceptional circumstances in adults. In a clinical trial where Twinrix Adult was administered according to this schedule, 82% and 85% of vaccinees had seroprotective levels of anti-HBV antibodies at 1 and 5 weeks respectively following the third dose (i.e. at months 1 and 2 after the initial dose). The seroprotection rate against hepatitis B increased to 95.1% by three months after the first dose.



Seropositivity rates for anti-HAV antibodies were 100%, 99.5% and 100% at months 1, 2 and 3 after the initial dose. One month after the fourth dose, all vaccinees demonstrated seroprotective levels of anti-HBs antibodies and were seropositive for anti-HAV antibodies.



In a clinical study conducted in subjects over 40 years of age, the seropositivity rate for anti-HAV antibodies and seroprotection rate against hepatitis B of Twinrix Adult following a 0, 1, 6 months schedule were compared with the seropositivity and seroprotection rates of monovalent hepatitis A and B vaccines when administered in opposite arms.



The seroprotection rate against hepatitis B after the administration of Twinrix Adult was 92% and 56% at 7 and 48 months respectively, versus 80% and 43% after the GlaxoSmithKline Biologicals monovalent 20µg hepatitis B vaccine, and 71% and 31% after another licensed monovalent 10µg hepatitis B vaccine. Anti-HBs antibody concentrations decreased as age and body mass index increased; they were also lower in male than in female subjects.



The seropositivity rate for anti-HAV antibodies after Twinrix Adult was 97% at both 7 and 48 months versus 99% and 93% after the GlaxoSmithKline Biologicals monovalent hepatitis A vaccine and 99% and 97% after another licensed monovalent hepatitis A vaccine.



Subjects received an additional dose of the same vaccine(s) 48 months after the first dose of the primary vaccination course. One month after this dose, 95% of the subjects vaccinated with Twinrix Adult achieved seroprotective levels of anti-HBV antibodies (



In two long term clinical studies conducted in adults aged 17 years to 43 years, 56 subjects had evaluable tests 15 years after the primary vaccination with Twinrix Adult; the anti-HAV seropositivity rates were 100% in both studies and the anti-HBs seroprotection rates were 89.3% and 92.9%, respectively. The kinetics of decline of anti-HAV and anti-HBs antibodies were shown to be similar to those of the monovalent vaccines.



5.2 Pharmacokinetic Properties



Evaluation of pharmacokinetic properties is not required for vaccines.



5.3 Preclinical Safety Data



Non-clinical data reveal no special hazard for humans based on general safety studies (see section 4.6).



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sodium chloride



Water for injections



For adjuvants, see section 2.



6.2 Incompatibilities



In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



Store in a refrigerator (2°C - 8°C).



Do not freeze.



Store in the original package, in order to protect from light.



6.5 Nature And Contents Of Container



1 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl).



Pack sizes of 1, 10 and 25.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



Upon storage, a fine white deposit with a clear colourless supernatant can be observed.



The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or abnormal physical appearanceprior to administration. In the event of either being observed, discard the vaccine.



Any unused product of waste material should be disposed of in accordance with local requirements.



7. Marketing Authorisation Holder



GlaxoSmithKline Biologicals s.a.



rue de l'Institut 89



B-1330 Rixensart, Belgium



8. Marketing Authorisation Number(S)



EU/1/96/020/004



EU/1/96/020/005



EU/1/96/020/006



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of first authorisation: 20 September 1996



Date of latest renewal: 20 September 2006



10. Date Of Revision Of The Text



23/06/2011





Mydrilate 1.0% Eye Drops





1. Name Of The Medicinal Product



Mydrilate 1.0 % Eye Drops


2. Qualitative And Quantitative Composition



Cyclopentolate Hydrochloride BP 1.0 % w/v.



3. Pharmaceutical Form



Eye drops.



4. Clinical Particulars



4.1 Therapeutic Indications



(i) Diagnostic purposes for fundoscopy and cycloplegic refraction.



(ii) Dilating the pupil in inflammatory conditions of the iris and uveal tract.



4.2 Posology And Method Of Administration



(i) Refraction / Fundoscopy



Adults (and the elderly):



One drop of 0.5 % solution instilled into the eye, repeated after 15 minutes if necessary, approximately 40 minutes before examination.



Deeply pigmented eyes may require the use of a 1 % solution.



NB: Maximum effect is reached after 30-60 minutes.



Children 6-16 years:



One drop of 1 % solution instilled into the eye, repeated after 15 minutes if necessary, approximately 40 minutes before examination.



Children under 6 years:



One or two drops of 1 % solution instilled into the eye, repeated after 15 minutes if necessary, approximately 40 minutes before examination.



(ii) For Uveitis, Iritis and Iridocyclitis:



Adults and the elderly:



One or two drops of 0.5 % solution instilled into the eye up to 4 times daily or as required.



Deeply pigmented eyes may require the use of a 1 % solution.



Children:



At the discretion of the physician



Do not use during the first three months of life due to possible association between the cycloplegia produced and the development of amblyopia and also the increased risks of systemic toxicity in neonates.



Cycloplegia following administration is quick in onset and short-lived. Maximal cycloplegia is achieved within 15 - 45 minutes of instillation and lasts on average about 20 minutes. Recovery normally takes place in about 4 hours, but very occasionally some effect persists for up to 24 hours.



Mydriasis is produced very rapidly and an average pupil diameter of 7 mm is usually reached 15 - 30 minutes after instillation of one drop of 0.5 % solution. Complete recovery from the mydriatic effect generally occurs spontaneously in not more than 20 hours.



No specific information on the use of this product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.



4.3 Contraindications



(i) Use in narrow-angle glaucoma or those with a tendency towards glaucoma e.g. patients with a shallow anterior chamber.



(ii) Hypersensitivity to cyclopentolate hydrochloride, benzalkonium chloride or any other components of the formulation.



(iii) This preparation contains benzalkonium chloride and should not be used whilst soft contact lenses are being worn.



(iv) Use in patients with paralytic ileus.



(v) Use in children with organic brain syndromes, including congenital or neuro-developmental abnormalities, particularly those predisposing to epileptic seizures.



4.4 Special Warnings And Precautions For Use



Because of the risk of precipitating angle-closure glaucoma in the elderly and others prone to raised intraocular pressure, an estimate of the depth of the anterior chamber should be made before use, particularly if therapy is likely to be intense or protracted.



Caution should be observed when drugs of this group are administered to patients with prostatic enlargement, coronary insufficiency or cardiac failure, or ataxia. Atropine-like effects have been reported as side-effects.



Extreme caution is advised for use in children and individuals susceptible to belladonna alkaloids because of the increased risk of systemic toxicity.



Patients should be warned of the oral toxicity of this preparation, and advised to wash their hands after use. If accidentally swallowed, patients should be advised to seek medical attention.



Use with caution in an inflamed eye as the hyperaemia greatly increases the rate of systemic absorption through the conjunctiva.



To reduce systemic absorption the lacrimal sac should be compressed at the medial canthus by digital pressure for at least two minutes after instillation of the drops.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



The effects of anti-muscarinic agents may be enhanced by the concomitant administration of other drugs with anti-muscarinic properties such as some antihistamines, butyrophenones, phenothiazines, tricyclic antidepressants and amantadine.



4.6 Pregnancy And Lactation



There is insufficient evidence as to drug safety in pregnancy and lactation. This product should not be used during pregnancy unless it is considered essential by a physician.



4.7 Effects On Ability To Drive And Use Machines



May cause blurred vision, difficulty in focusing and sensitivity to light. Patients should be warned not to drive or engage in other hazardous activities (including climbing ladders and scaffolding) unless vision is clear. Complete recovery from the effects of Mydrilate Eye Drops may take up to 24 hours.



4.8 Undesirable Effects



(i) Local:



Increased intraocular pressure, transient stinging, and sensitivity to light secondary to pupillary dilation. Prolonged administration may lead to local irritation, hyperaemia, oedema and conjunctivitis.



(ii) Systemic:



Systemic anticholinergic toxicity is manifested by dryness of the mouth, flushing, dryness of the skin, bradycardia followed by tachycardia with palpitations and arrhythmias, urinary urgency, difficulty and retention, reduction in the tone and motility of the gastrointestinal tract leading to constipation.



(iii) Vomiting, giddiness and staggering may occur, a rash may be present in children, abdominal distension in infants. Psychotic reactions, behavioural disturbances and cardio-respiratory collapse may occur in children.



4.9 Overdose



Systemic toxicity may occur following topical use, particularly in children. It is manifested by flushing and dryness of the skin (a rash may be present in children), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, convulsions and hallucinations and the loss of neuromuscular co-ordination.



Treatment is supportive (there is no evidence that physostigmine is superior to supportive management). In infants and small children the body surface must be kept moist. If accidentally ingested, induce emesis or perform gastric lavage.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Cyclopentolate is an anti-muscarinic agent used topically in the eye as a mydriatic and cycloplegic. The effects are similar to those of atropine, but with a more rapid onset and a shorter duration of action.



5.2 Pharmacokinetic Properties



None stated.



5.3 Preclinical Safety Data



None stated.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Boric acid



Potassium chloride



Benzalkonium chloride solution



Purified water.



6.2 Incompatibilities



None stated.



6.3 Shelf Life



2 years.



6.4 Special Precautions For Storage



Store at 2-8oC. Refrigerate, do not freeze. Protect from light. Do not dilute or dispense from any container other than the original bottle. Discard one month after opening.



6.5 Nature And Contents Of Container



5 ml dropper bottle of 1.0 % solution.







Bottle:

LE 6601 PH (LDPE)


Natural colour



Cap:

Melochem


White colour



6.6 Special Precautions For Disposal And Other Handling



When using the product for the first time, screw down the cap firmly on the bottle to pierce the seal at the tip of the plastic nozzle and unscrew the cap for use.



7. Marketing Authorisation Holder



Intrapharm Laboratories Ltd



60 Boughton Lane



Maidstone



Kent



ME15 9QS



United Kingdom



8. Marketing Authorisation Number(S)



PL 17509/0008



9. Date Of First Authorisation/Renewal Of The Authorisation



8 August 2001



10. Date Of Revision Of The Text



June 2003



11. Legal category


POM





Sectral 100mg and 200mg capsules





1. Name Of The Medicinal Product



Sectral 100mg Capsules



Sectral 200mg Capsules


2. Qualitative And Quantitative Composition



Each capsule contains 111mg of the active substance Acebutolol hydrochloride (equivalent to 100mg of base).



Each capsule contains 222mg of the active substance Acebutolol hydrochloride (equivalent to 200mg of base).



For a full list of excipients, see section 6.1



3. Pharmaceutical Form



Sectral 100mg Capsules: Capsule. Hard gelatin capsules, the bodies being opaque yellowish-buff and the caps opaque white in colour. Length approximately 17mm, diameter of body approximately 6mm. Both body and cap are printed in black: Sectral 100.



Sectral Capsules 200: Capsule. Hard gelatin capsules, the bodies being opaque yellowish-buff and the caps opaque pink in colour. Length approximately 17mm, diameter of body approximately 6mm. Both body and cap are printed in black: Sectral 200



The capsules contain a white or almost white powder.



4. Clinical Particulars



4.1 Therapeutic Indications



The management of all grades of hypertension, angina pectoris and the control of tachyarrhythmias.



4.2 Posology And Method Of Administration



Hypertension: Initial dosage of 400mg orally once daily at breakfast or 200mg orally twice daily. If response is not adequate within two weeks, dosage may be increased up to 400mg orally twice daily; if the hypertension is still not adequately controlled consideration should be given to adding a second antihypertensive agent such as the calcium antagonist nifedipine or small doses of a thiazide diuretic.



Angina pectoris: Initial dosage of 400mg orally once daily at breakfast or 200mg twice daily. In severe forms up to 300mg three times daily may be required. Up to 1200mg daily has been used.



Cardiac Arrhythmias: When given orally, an initial dose of 200mg is recommended. The daily dose requirement for long term anti arrhythmic activity should lie between 400 and 1200mg daily. The dose can be gauged by response, and better control may be achieved by divided doses rather than single doses. It may take up to three hours for maximal anti-arrhythmic effect to become apparent.



Elderly: There are no specific dosage recommendations for the elderly with normal glomerular filtration rate. Dose reduction is necessary if moderate to severe renal impairment is present (see Section 4.4)



Children: Paediatric dose has not been established.



For all indications, it is advised that the lowest recommended dosage be used initially.



4.3 Contraindications



Cardiogenic shock is an absolute contraindication. Extreme caution is required in patients with blood pressures of the order of 100/60 mmHg or below. Sectral is also contraindicated in patients with second and third degree heart block, sick sinus syndrome, marked bradycardia (< 45-50 bpm), uncontrolled heart failure, metabolic acidosis, severe peripheral circulatory disorders, hypersensitivity to acebutolol, any of the excipients or to beta blockers, and untreated phaeochromocytoma.



4.4 Special Warnings And Precautions For Use



Renal impairment is not a contraindication to the use of Sectral which has both renal and non-renal excretory pathways. Some caution should be exercised when administering high doses to patients with severe renal failure as accumulation could possibly occur in these circumstances.



The dosage frequency should not exceed once daily in patients with renal impairment. As a guide, the dosage should be reduced by 50% when glomerular filtration rates are between 25-50ml/min and by 75% when they are below 25ml/min (see Section 4.2).



Drug-induced bronchospasm is usually at least partially reversible by the use of a suitable agonist.



Although cardio-selective beta blockers may have less effect on lung function than non-selective beta blockers as with all beta blockers they should be avoided in patients with obstructive airways disease unless there are compelling clinical reasons for their use. Where such reasons exist, cardio-selective β-blockers should be used with the utmost care (see Section 4.3).



Beta-blockers may induce bradycardia. In such cases, the dosage should be reduced.



They may be used with care in patients with controlled heart failure (see Section 4.3).



Use with caution in patients with Prinzmetal's angina.



Beta blockers may aggravate peripheral circulatory disorders. They may mask signs of thyrotoxicosis and hypoglycaemia. They should only be used in patients with phaeochromocytoma with concomitant alpha-adrenoceptor therapy



Patients with known psoriasis should take beta-blockers only after careful consideration.



Beta-blockers may increase both the sensitivity towards allergens and the seriousness of anaphylactic reactions.



Withdrawal of treatment by beta blockers should be achieved by gradual dosage reduction; this is especially important in patients with ischaemic heart disease



When it has been decided to interrupt beta-blockade prior to surgery, therapy should be discontinued for at least 24 hours. Continuation of therapy reduces the risk of arrhythmias but the risk of hypotension may be increased. If treatment is continued, caution should be observed with the use of certain anaesthetic drugs. The patient may be protected against vagal reactions by intravenous administration of atropine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Sectral should not be used with Verapamil or within several days of Verapamil therapy (and vice versa). Use with great care with any other calcium antagonists, particularly Diltiazem.



Class I anti-arrhythmic drugs (such as disopyramide) and amiodarone may increase atrial conduction time and induce negative inotropic effects when used concomitantly with beta-blockers.



In patients with labile and insulin-dependent diabetes, the dosage of the hypoglycaemic agent (ie insulin or oral diabetic drugs) may need to be reduced. However beta-blockers have also been known to blunt the effect of glibenclamide. Beta-adrenergic blockade may also prevent the appearance of signs of hypoglycaemia (tachycardia, see Section 4.4).



Cross reactions due to displacement of other drugs from plasma protein binding sites are unlikely due to the low degree of plasma protein binding exhibited by acebutolol and diacetolol.



If a beta-blocker is used concurrently with clonidine the latter should not be withdrawn until several days after the former is discontinued.



Acebutolol may antagonize the effect of sympathomimetic and xanthine bronchodilators.



Concurrent use of digoxin and beta blockers may occasionally induce serious bradycardia. The anti-hypertensive effects of beta blockers may be attenuated by non-steroidal anti-inflammatory agents.



Concomitant administration of tricyclic antidepressants, barbiturates and phenothiazines as well as other anti-hypertensive agent- may increase the blood pressure lowering effect of beta-blockers.



There is a theoretical risk that concurrent administration of monoamine oxidase inhibitors and high doses of beta-blockers, even if they are cardio-selective can produce hypertension.



Sectral therapy should be brought to the attention of the anaesthetist prior to general anaesthesia (see Section 4.4). If treatment is continued, special care should be taken when using anaesthetic agents causing myocardial depression such as ether, cyclopropane and trichlorethylene.



4.6 Pregnancy And Lactation



Pregnancy: Acebutolol should not be administered to female patients during the first trimester of pregnancy unless the physician considers it essential. In such cases the lowest possible dose should be used.



Beta blockers administered in late pregnancy may give rise to bradycardia, hypoglycaemia and cardiac or pulmonary complications in the foetus/neonate.



Beta-blockers can reduce placental perfusion, which may result in intrauterine foetal death, immature and premature deliveries.



Animal studies have shown no teratogenic hazard.



Lactation: Acebutolol and its active metabolites are excreted in human milk and effects have been shown in breastfed newborns/infants of treated mothers. Acebutolol should not be used during breast-feeding.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed. As with all beta-blockers, dizziness or fatigue may occur occasionally. This should be taken into account when driving or operating machinery.



4.8 Undesirable Effects



Adverse reactions associated with acebutolol during controlled clinical trials in patients with hypertension, angina pectoris or arrhythmia (1002 patients exposed to acebutolol) are presented by system organ class and by decreasing order of frequency.



The frequency of the events “anti-nuclear antibody” and “lupus like syndrome” was found from 1440 patients suffering from hypertension, angina pectoris or arrhythmia and exposed to acebutolol in open or double blind studies performed in the United States.



Frequencies are defined as: very common (



When the exact frequency of the event was not reported, the frequency category assigned is “not known” (ADRs with *).



Adverse reactions reported from post-marketing experience are also listed. These adverse reactions are derived from spontaneous reports and therefore, the frequency of these adverse reactions is “not known” (cannot be estimated from the available data).



The most frequent and serious adverse reactions of acebutolol are related to the beta-adrenergic blocking activity. The most frequent reported clinical adverse reactions are fatigue and gastrointestinal disorders. Among the most serious adverse reactions are cardiac failure, atrioventricular block and bronchospasm. Abrupt withdrawal as for all beta-blockers may exacerbate angina pectoris and precaution is especially required in patients with ischaemic heart disease (see Section 4.4).


























































Immune system disorders




Very common




Antinuclear antibody




Uncommon




Lupus like syndrome


 


Psychiatric disorders




Common




Depression, nightmare




Not known




Pychoses, hallucinations, confusion, loss of libido*, sleep disorder


 


Nervous system disorders




Very common




Fatigue




Common




Dizziness, headache


 


Not known




Paraesthesia*, central nervous system disorder


 


Eye disorders




Common




Visual impairment




Not known




Dry eye*


 


Cardiac disorders




Not known




Cardiac failure*, atrioventricular block first degree, increase of an existing atrioventricular block, bradycardia*




Vascular disorders




Not known




Intermittent claudication, Raynaud's syndrome, cyanosis peripheral and peripheral coldness, hypotension*




Respiratory, thoracic and mediastinal disorders




Common




Dyspnoea




Not known




Pneumonitis, lung infiltration, bronchospasm


 


Gastrointestinal disorders




Very common




Gastrointestinal disorders




Common




Nausea, diarrhoea


 


Not known




Vomiting*


 


Skin and subcutaneous tissue disorders




Common




Rash




General disorders and administration site condition




Not known




Withdrawal syndrome (see Section 4.4)



4.9 Overdose



In the event of excessive bradycardia or hypotension, 1mg atropine sulphate administered intravenously should be given without delay. If this is insufficient it should be followed by a slow intravenous injection of isoprenaline (5mcg per minute) with constant monitoring until a response occurs. In severe cases of self-poisoning with circulatory collapse unresponsive to atropine and catecholamines the intravenous injection of glucagon 10-20mg may produce a dramatic improvement. Cardiac pacing may be employed if bradycardia becomes severe.



Judicious use of vasopressors, diazepam, phenytoin, lidocaine, digoxin and bronchodilators should be considered depending on the presentation of the patient. Acebutolol can be removed from blood by haemodialysis. Other symptoms and signs of overdosage include cardiogenic shock, AV block, conduction defects, pulmonary oedema, depressed level of consciousness, bronchospasm, hypoglycaemia and rarely hyperkalaemia.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Beta Blocking agents; Beta blocking agents, selective, ATC code: C07AB04



Mode of action: Sectral is a beta adrenoceptor antagonist which is cardioselective, i.e. acts preferentially on beta-1 adrenergic receptors in the heart. Its principal effects are to reduce heart rate especially on exercise and to lower blood pressure in hypertensive subjects. Sectral and its equally active metabolite, diacetolol have anti-arrhythmic activity, the combined plasma half-life of the active drug and metabolite being 7-10 hours. Both have partial agonist activity (PAA) also known as intrinsic sympathomimetic activity (ISA). This property ensures that some degree of stimulation of beta receptors is maintained. Under conditions of rest, this tends to balance the negative chronotropic and negative inotropic effects. Sectral blocks the effects of excessive catecholamine stimulation resulting from stress.



5.2 Pharmacokinetic Properties



After oral administration, acebutolol is rapidly and almost completely absorbed. Absorption appears to be unaffected by the presence of food in the gut. There is rapid formation of a major equiactive metabolite, diacetolol, which possesses a similar pharmacological profile to acebutolol. Peak plasma concentrations of active material (i.e. acebutolol plus diacetolol) are achieved within 2-4 hours and the terminal plasma elimination half-life is around 8-10 hours. Because of biliary excretion and direct transfer across the gut wall from the systemic circulation to the gut lumen, more than 50% of an oral dose of Sectral is recovered in the faeces with acebutolol and diacetolol in equal proportions; the rest of the dose is recovered in the urine, mainly as diacetolol. Both acebutolol and diacetolol are hydrophilic and exhibit poor penetration of the CNS.



5.3 Preclinical Safety Data



No particulars.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sectral capsules: Starch Potato, Silica colloidal anhydrous (E551), Magnesium Stearate (E572).



Sectral 100mg Capsule Shell:



Body: Yellow iron oxide (E172), Titanium dioxide (E171), Gelatin



Cap: Titanium dioxide (E171), Gelatin,



Ink: Opacode S-1-8100 Black containing Shellac glaze, Black Iron oxide (E172), Lecithin, Antifoam DC 1501



Sectral 200mg Capsule Shell:



Body: Yellow iron oxide (E172), Titanium dioxide (E171), Gelatin



Cap: Titanium dioxide (E171), Gelatin, Red iron oxide (E172),



Ink: Opacode S-1-8100 Black containing Shellac glaze, Black iron oxide (E172), Lecithin, Antifoam DC 1501.



6.2 Incompatibilities



Not applicable



6.3 Shelf Life



5 years



6.4 Special Precautions For Storage



Store below 25°C. Store in the original package in order to protect from light and moisture.



6.5 Nature And Contents Of Container



Sectral Capsules 100mg: Aluminium foil/UPVC blister strip packs of 84 capsules.



Sectral Capsules 200mg: Aluminium foil/UPVC blister strip packs of 56 capsules.



6.6 Special Precautions For Disposal And Other Handling



No special requirements



7. Marketing Authorisation Holder



Sanofi-aventis



One Onslow Street



Guildford



Surrey, GU1 4YS, UK



8. Marketing Authorisation Number(S)



Sectral Capsules 100mg: PL 4425/0262



Sectral Capsules 200mg: PL 4425/0263



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of first authorisation: 16 December 1974



Date of latest renewal: 12 July 2003



10. Date Of Revision Of The Text



6th July 2011



LEGAL CLASSIFICATION


POM





Wednesday, October 26, 2016

Glimepiride 3mg Tablet





1. Name Of The Medicinal Product



Glimepiride 3mg Tablet


2. Qualitative And Quantitative Composition



Each tablet contains 3mg glimepiride.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Tablet



The tablets are pale yellow, oblong and scored on both sides.



4. Clinical Particulars



4.1 Therapeutic Indications



Glimepiride is indicated for the treatment of type II diabetes mellitus, when diet, physical exercise and weight reduction alone are not adequate.



4.2 Posology And Method Of Administration



For oral administration.



The basis for successful treatment of diabetes is a good diet, regular physical activity, as well as routine checks of blood and urine. Tablets or insulin cannot compensate if the patient does not keep to the recommended diet.



Dosage is determined by the results of blood and urinary glucose determinations.



The starting dose is 1 mg glimepiride per day. If good control is achieved this dosage should be used for maintenance therapy.



For the different dosage regimens appropriate strengths are available.



If control is unsatisfactory the dosage should be increased, based on the glycaemic control, in a stepwise manner with an interval of about 1 to 2 weeks between each step, to 2, 3 or 4 mg glimepiride per day.



A dosage of more than 4 mg glimepiride per day gives better results only in exceptional cases. The maximum recommended dose is 6 mg glimepiride per day.



In patients not adequately controlled with the maximum daily dose of metformin, concomitant glimepiride therapy can be initiated.



While maintaining the metformin dose, the glimepiride therapy is started with a low dose, and is then titrated up depending on the desired level of metabolic control up to the maximum daily dose. The combination therapy should be initiated under close medical supervision.



In patients not adequately controlled with the maximum daily dose of glimepiride, concomitant insulin therapy can be initiated if necessary. While maintaining the glimepiride dose, insulin treatment is started at low dose and titrated up depending on the desired level of metabolic control. The combination therapy should be initiated under close medical supervision.



Normally a single daily dose of glimepiride is sufficient. It is recommended that this dose be taken shortly before or during a substantial breakfast or



If a dose is forgotten, this should not be corrected by increasing the next dose. Tablets should be swallowed whole with some liquid.



If a patient has a hypoglycaemic reaction on 1 mg glimepiride daily, this indicates that they can be controlled by diet alone.



In the course of treatment, as an improvement in control of diabetes is associated with higher insulin sensitivity, glimepiride requirements may fall. To avoid hypoglycaemia timely dose reduction or cessation of therapy must therefore be considered. Change in dosage may also be necessary, if there are changes in weight or life style of the patient, or other factors that increase the risk of hypo-or hyperglycaemia.



Switch over from other oral hypoglycaemic agents to glimepiride



A switch over from other oral hypoglycaemic agents to glimepiride can generally be done. For the switch over to glimepiride the strength and the half-life of the previous medicinal product has to be taken into account. In some cases, especially in antidiabetics with a long half-life (e.g. chlorpropamide), a wash out period of a few days is advisable in order to minimise the risk of hypoglycaemic reactions due to the additive effect.



The recommended starting dose is 1 mg glimepiride per day. Based on the response the glimepiride dosage may be increased stepwise, as indicated earlier.



Switch over from Insulin to glimepiride



In exceptional cases, where type 2 diabetic patients are regulated on insulin, a changeover to glimepiride may be indicated. The changeover should be undertaken under close medical supervision.



Special Populations



Patients with renal or hepatic impairment:



See section 4.3.



Children and adolescents:



There are no data available on the use of glimepiride in patients under 8 years of age. For children aged 8 to 17 years, there are limited data on glimepiride as monotherapy (see sections 5.1 and 5.2).



The available data on safety and efficacy are insufficient in the paediatric population and therefore such use is not recommended.



4.3 Contraindications



Glimepiride is contraindicated in patients with the following conditions:



• hypersensitivity to glimepiride, other sulfonylureas or sulfonamides or to any of the excipients,



• insulin dependent diabetes,



• diabetic coma,



• ketoacidosis,



• severe renal or hepatic function disorders.In case of severe renal or hepatic function disorders, a change over to insulin is required.



4.4 Special Warnings And Precautions For Use



Glimepiride must be taken shortly before or during a meal.



When meals are taken at irregular hours or skipped altogether, treatment with glimepiride may lead to hypoglycaemia. Possible symptoms of hypoglycaemia include: headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, alertness and reaction time, depression, confusion, speech and visual disorders, aphasia, tremor, paresis, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence and loss of consciousness up to and including coma, shallow respiration and bradycardia. In addition, signs of adrenergic counter-regulation may be present such as sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmias.



The clinical picture of a severe hypoglycaemic attack may resemble that of a stroke.



Symptoms can almost always be promptly controlled by immediate intake carbohydrates (sugar). Artificial sweeteners have no effect.



It is known from other sulfonylureas that, despite initially successful countermeasures, hypoglycaemia may recur.



Severe hypoglycaemia or prolonged hypoglycaemia, only temporarily controlled by the usual amounts of sugar, require immediate medical treatment and occasionally hospitalisation.



Factors favouring hypoglycaemia include:



• unwillingness or (more commonly in older patients) incapacity of the patient to cooperate,



• undernutrition, irregular mealtimes or missed meals or periods of fasting,



• alterations in diet,



• imbalance between physical exertion and carbohydrate intake,



• consumption of alcohol, especially in combination with skipped meals,



• impaired renal function,



• serious liver dysfunction,



• overdosage with glimepiride,



• certain uncompensated disorders of the endocrine system affecting carbohydrate metabolism or counterregulation of hypoglycaemia (as for example in certain disorders of thyroid function and in anterior pituitary or adrenocortical insufficiency), concurrent administration of certain other medicinal products (see section 4.5).



Treatment with glimepiride requires regular monitoring of glucose levels in blood and urine. In addition determination of the proportion of glycosylated haemoglobin is recommended.



Regular hepatic and haematological monitoring (especially leucocytes and thrombocytes) are required during treatment with glimepiride.



In stress-situations (e.g. accidents, acute operations, infections with fever, etc.) a temporary switch to insulin may be indicated.



No experience has been gained concerning the use of glimepiride in patients with severe impairment of liver function or dialysis patients. In patients with severe impairment of renal or liver function change over to insulin is indicated.



Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to hemolytic anaemia. Since glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.



Glimepiride tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



If glimepiride is taken simultaneously with certain other medicinal products, both undesired increases and decreases in the hypoglycaemic action of glimepiride can occur. For this reason, other medicinal products should only be taken with the knowledge (or at the prescription) of the doctor.



Glimepiride is metabolized by cytochrome P450 2C9 (CYP2C9). Its metabolism is known to be influenced by concomitant administration of CYP2C9 inducers (e.g rifampicin) or inhibitors (e.g fluconazole).



Results from an vivo interaction study reported in literature show that glimepiride AUC is increased approximately 2-fold by fluconazole, one of the most potent CYP2C9 inhibitors.



Based on the experience with glimepiride and with other sulfonylureas the following interactions have to be mentioned.



Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur when one of the following medicinal products is taken, for example:




































- phenylbutazone, azapropazon and oxyfenbutazone,



 


- insulin and oral antidiabetic products, such as metformin



 


- salicylates and p



 


- anabolic steroids and male sex hormones,



 


- chloramphenicol, certain long acting sulfonamides, tetracyclines, quinolone antibiotics and clarithromycin



 


- coumarin anticoagulants,



 


- fenfluramine,



 


- fibrates,



 


- ACE inhibitors,



 


- fluoxetine, MAO-inhibitors,



 


- allopurinol, probenecid, sulfinpyrazone,



 


- sympatholytics,



 


- cyclophosphamide, trophosphamide and iphosphamides,



 


- miconazol, fluconazole,



 


- pentoxifylline (high dose parenteral),



 


- tritoqualine.



 


Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of the following medicinal products is taken, for example:



oestrogens and progestogens,



saluretics, thiazide diuretics,



thyroid stimulating agents, glucocorticoids,



phenothiazine derivatives, chlorpromazine,



adrenaline and sympathicomimetics,



nicotinic acid (high dosages) and nicotinic acid derivatives,



laxatives (long term use),



phenytoin, diazoxide,



glucagon, barbiturates and rifampicin,



acetazolamide.



H2 antagonists, betablockers, clonidine and reserpine may lead to either potentiation or weakening of the blood glucose lowering effect.



Under the influence of sympatholytic medicinal products such as betablockers, clonidine, guanethidine and reserpine, the signs of adrenergic counterregulation to hypoglycaemia may be reduced or absent.



Alcohol intake may potentiate or weaken the hypoglycaemic action of glimepiride in an unpredictable fashion.



Glimepiride may either potentiate or weaken the effects of coumarin derivatives



4.6 Pregnancy And Lactation



Pregnancy



Risk related to the diabetes



Abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities and perinatal mortality. So the blood glucose level must be closely monitored during pregnancy in order to avoid the teratogenic risk. The use of insulin is required under such circumstances. Patients who consider pregnancy should inform their physician.



Risk related to glimepiride



There are no adequate data from the use of glimepiride in pregnant women. Animal studies have shown reproductive toxicity which likely was related to the pharmacologic action (hypoglycaemia) of glimepiride (see section 5.3).



Consequently, glimepiride should not be used during the whole pregnancy.



In case of treatment by glimepiride, if the patient plans to become pregnant or if a pregnancy is discovered, the treatment should be switched as soon as possible to insulin therapy.



Lactation



The excretion in human milk is unknown. Glimepiride is excreted in rat milk. As other sulfonylureas are excreted in human milk and because there is a risk of hypoglycaemia in nursing infants, breast-feeding is advised against during treatment with glimepiride.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).



Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machinery in these circumstances.



4.8 Undesirable Effects



The following adverse reactions from clinical investigations are based on experience with glimepiride and other sulfonylureas, and are listed below by system organ class and in order of decreasing incidence (very common:



Blood and lymphatic system disorders



Rare: thrombocytopenia, leukopenia, , granulocytopenia, agranulocytosis, erythropenia, haemolytic anaemia and pancytopenia, which are in general reversible upon discontinuation of medication.



Immune system disorders



Very rare: leukocytoclastic vasculitis, mild hypersensitivity reactions that may develop into serious reactions with dyspnoea, fall in blood pressure and sometimes shock.



Not known:cross-allergenicity with sulfonylureas, sulfonamides or related substances is possible.



Metabolism and nutrition disorders



Rare: hypoglycaemia.



These hypoglycaemic reactions mostly occur immediately, may be severe and are not always easy to correct.The occurrence of such reactions depends, as with other hypoglycaemic therapies, on individual factors such as dietary habits and the dosage (see further under section 4.4).



Eye disorders



Not known:visual disturbances, transient, may occur especially on initiation of treatment, due to changes in blood glucose levels.



Gastrointestinal disorders



Very rare: nausea, vomiting, diarrhoea, abdominal distension, abdominal discomfort and abdominal pain, which seldom lead to discontinuation of therapy.



Hepato-biliary disorders



Not known:hepatic enzymes increased.



Very rare: hepatic function abnormal (e.g. with cholestasis and jaundice) , hepatitis and hepatic failure.



Skin and subcutaneous tissue disorders



Not known:hypersensitivity reactions of the skin may occur as pruritus, rash urticaria and photosensitivity.



Investigations



Very rare: blood sodium decrease.



4.9 Overdose



After ingestion of an overdosage hypoglycaemia may occur, lasting from 12 to 72 hours, and may recur after an initial recovery. Symptoms may not be present for up to 24 hours after ingestion. In general observation in hospital is recommended. Nausea, vomiting and epigastric pain may occur. The hypoglycaemia may in general be accompanied by neurological symptoms like restlessness, tremor, visual disturbances, co-ordination problems, sleepiness, coma and convulsions.



Treatment primarily consists of preventing absorption by inducing vomiting and then drinking water or lemonade with activated charcoal (adsorbent) and sodium-sulphate (laxative). If large quantities have been ingested, gastric lavage is indicated, followed by activated charcoal and sodium-sulphate. In case of (severe) overdosage hospitalisation in an intensive care department is indicated. Start the administration of glucose as soon as possible, if necessary by a bolus intravenous injection of 50 ml of a 50% solution, followed by an infusion of a 10% solution with strict monitoring of blood glucose. Further treatment should be symptomatic.



In particular when treating hypoglycaemia due to accidental intake of Glimepiride Winthrop in infants and young children, the dose of glucose given must be carefully controlled to avoid the possibility of producing dangerous hyperglycaemia. Blood glucose should be closely monitored.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Blood glucose lowering drugs, excl. insulins: Sulfonamides, urea derivatives. ATC Code: A10B B12.



Glimepiride is an orally active hypoglycaemic substance belonging to the sulfonylurea group. It may be used in non-insulin dependent diabetes mellitus.



Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.



As with other sulfonylureas this effect is based on an increase of responsiveness of the pancreatic beta cells to the physiological glucose stimulus. In addition, glimepiride seems to have pronounced extrapancreatic effects also postulated for other sulfonylureas.



Insulin release



Sulfonylureas regulate insulin secretion by closing the ATP-sensitive potassium channel in the beta cell membrane. Closing the potassium channel induces depolarisation of the beta cell and results



This leads to insulin release through exocytosis.



Glimepiride binds with a high exchange rate to a beta cell membrane protein which is associated with the ATP-sensitive potassium channel but which is different from the usual sulfonylurea binding site.



Extrapancreatic activity



The extrapancreatic effects are for example an improvement of the sensitivity of the peripheral tissue for insulin and a decrease of the insulin uptake by the liver.



The uptake of glucose from blood into peripheral muscle and fat tissues occurs via special transport proteins, located in the cells membrane. The transport of glucose in these tissues is the rate limiting step in the use of glucose. Glimepiride increases very rapidly the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulated glucose uptake.



Glimepiride increases the activity of the glycosyl-phosphatidylinositol-specific phospholipase C which may be correlated with the drug-induced lipogenesis and glycogenesis in isolated fat and muscle cells.



Glimepiride inhibits the glucose production in the liver by increasing the intracellular concentration of fructose-2,6



General



In healthy persons, the minimum effective oral dose is approximately 0.6 mg. The effect of glimepiride is dose-dependent and reproducible. The physiological response to acute physical exercise, reduction of insulin secretion, is still present under glimepiride.



There was no significant difference in effect regardless of whether the medicinal product was given 30 minutes or immediately before a meal. In diabetic patients, good metabolic control over 24 hours can be achieved with a single daily dose.



Although the hydroxy metabolite of glimepiride caused a small but significant decrease in serum glucose in healthy persons, it accounts for only a minor part of the total drug effect.



Combination therapy with metformin



Improved metabolic control for concomitant glimepiride therapy compared to metformin alone in patients not adequately controlled with the maximum dosage of metformin has been shown in one study.



Combination therapy with insulin



Data for combination therapy with insulin are limited. In patients not adequately controlled with the maximum dosage of glimepiride, concomitant insulin therapy can be initiated. In two studies, the combination achieved the same improvement in metabolic control as insulin alone; however, a lower average dose of insulin was required in combination therapy.



Special populations



Children and adolescents



An active controlled clinical trial (glimepiride up to 8 mg daily or metformin up to 2,000 mg daily) of 24 weeks duration was performed in 285 children (8-17 years of age) with type 2 diabetes.



Both glimepiride and metformin exhibited a significant decrease from baseline in HbA1c (glimepiride -0.95 (se 0.41); metformin -1.39 (se 0.40)). However, glimepiride did not achieve the criteria of non-inferiority to metformin in mean change from baseline of HbA1c. The difference between treatments was 0.44% in favour of metformin. The upper limit (1.05) of the 95% confidence interval for the difference was not below the 0.3% non-inferiority margin.



Following glimepiride treatment, there were no new safety concerns noted in children compared to adult patients with type 2 diabetes mellitus. No long-term efficacy and safety data are available in paediatric patients.



5.2 Pharmacokinetic Properties



Absorption: The bioavailability of glimepiride after oral administration is complete. Food intake has no relevant influence on absorption, only absorption rate is slightly diminished. Maximum serum concentrations (Cmax) are reached approx. 2.5 hours after oral intake (mean 0.3 µg/ml during multiple dosing of 4 mg daily) and there is a linear relationship between dose and both Cmax and AUC (area under the time/concentration curve).



Distribution: Glimepiride has a very low distribution volume (approx. 8.8 litres) which is roughly equal to the albumin distribution space, high protein binding (>99%), and a low clearance (approx. 48 ml/min).



In animals, glimepiride is excreted in milk. Glimepiride is transferred to the placenta. Passage of the blood brain barrier is low.



Biotransformation and elimination: Mean dominant serum half-life, which is of relevance for the serum concentrations under multiple-dose conditions, is about 5 to 8 hours. After high doses, slightly longer half-lives were noted.



After a single dose of radiolabelled glimepiride, 58% of the radioactivity was recovered in the urine, and 35% in the faeces. No unchanged substance was detected in the urine. Two metabolites



Comparison of single and multiple once-daily dosing revealed no significant differences in pharmacokinetics, and the intraindividual variability was very low. There was no relevant accumulation.



Special populations



Pharmacokinetics were similar in males and females, as well as in young and elderly (above 65 years) patients. In patients with low creatinine clearance, there was a tendency for glimepiride clearance to increase and for average serum concentrations to decrease, most probably resulting from a more rapid elimination because of lower protein binding. Renal elimination of the two metabolites was impaired. Overall no additional risk of accumulation is to be assumed in such patients.



Pharmacokinetics in five non-diabetic patients after bile duct surgery were similar to those in healthy persons.



Children and adolescents



A fed study investigating the pharmacokinetics, safety, and tolerability of a 1 mg single dose of glimepiride in 30 paediatric patients (4 children aged 10-12 years and 26 children aged 12-17 years) with type 2 diabetes showed mean AUC(0-last) , Cmax and t1/2 similar to that previously observed in adults.



5.3 Preclinical Safety Data



Preclinical effects observed occurred at exposures sufficiently in excess of the maximum human exposure as to indicate little relevance to clinical use, or were due to the pharmacodynamic action (hypoglycaemia) of the compound. This finding is based on conventional safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and reproduction toxicity studies. In the latter (covering embryotoxicity, teratogenicity and developmental toxicity), adverse effects observed were considered to be secondary to the hypoglycaemic effects induced by the compound in dams and in offspring.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Lactose monohydrate



sodium starch glycollate (type A)



magnesium stearate



microcrystalline cellulose



povidone 25000



Colouring agents



Yellow iron oxide (E172)



6.2 Incompatibilities



Not applicable



6.3 Shelf Life



3 years



6.4 Special Precautions For Storage



Do not store above 30 °C.



Store in the original package in order to protect from moisture.



6.5 Nature And Contents Of Container



White/opaque PVC/Aluminium blisters or clear/bluish PVC/Aluminium blisters.



15, 20, 30, 50, 60, 90 and 120 tablets



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements



7. Marketing Authorisation Holder



Winthrop Pharmaceuticals UK Limited



One Onslow Street



Guildford



Surrey



GU1 4YS



UK



8. Marketing Authorisation Number(S)



PL 17780/0003



9. Date Of First Authorisation/Renewal Of The Authorisation



26/01/2010



10. Date Of Revision Of The Text



January 2010



Legal status


POM